After moxibustion treatment, the level of sPD-1 and sPD-L1 decreased in the Mox group compared with the RA group (Figures 2(a) and 2(b), Mox group: sPD-1: 4.73 ± 0.78, sPD-L1: 1.20 ± 0.28). The gene discussed is HOXD13; the disease is rheumatoid arthritis.